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Abstract
Co-infection with HIV and P. falciparum worsens the prognosis of both infections; however, the mechanisms driving this
adverse interaction are not fully delineated. To evaluate this, we studied HIV-1 and P. falciparum interactions in vitro using
peripheral blood mononuclear cells (PBMCs) from human malaria naı ¨ve volunteers experimentally infected with P.
falciparum in a malaria challenge trial.PBMCs collected before the malaria challenge and at several time points post-
infection were infected with HIV-1 and co-cultured with either P. falciparum infected (iRBCs) or uninfected (uRBCs) red blood
cells. HIV p24Ag and TNF-a, IFN-c, IL-4, IL-6, IL-10, IL-17, and MIP-1a were quantified in the co-culture supernatants. In
general, iRBCs stimulated more HIV p24Ag production by PBMCs than did uRBCs. HIV p24Ag production by PBMCs in the
presence of iRBCs (but not uRBCs) further increased during convalescence (days 35, 56, and 90 post-challenge). In parallel,
iRBCs induced higher secretion of pro-inflammatory cytokines (TNF-a, IFN-c, and MIP-1a) than uRBCs, and production
increased further during convalescence. Because the increase in p24Ag production occurred after parasitemia and
generalized immune activation had resolved, our results suggest that enhanced HIV production is related to the
development of anti-malaria immunity and may be mediated by pro-inflammatory cytokines.
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Introduction
HIV-1 and Plasmodium falciparum malaria remain two of Sub-
Saharan Africa’s major causes of morbidity and mortality.
Together malaria and HIV caused nearly 2.5 million deaths in
Africa during 2008. Although it was not initially fully appreciated
[1,2], increasing evidence indicates that the two pathogens interact
in individuals and in populations. During acute bouts of clinical
malaria, plasma HIV-1 RNA levels rise [3–5], and CD4 cells
decline by approximately 40 cells/mL/year with each malaria
episode [6] compared to the rate of decline in individuals without
clinical malaria episodes. Conversely, in regions of unstable
malaria transmission, HIV infection is associated with increased
malaria disease severity and death [7]. Recently, a mathematical
model further explored the potential importance of the malaria/
HIV interaction. Based on this model, in an area of Kenya, with
an adult population of roughly 200,000 that has been exposed to
both pathogens since 1980, the interaction of the two diseases may
have caused 8,500 excess HIV infections and 980,000 excess
malaria episodes [8]. Supporting this mathematical model, a study
that examined geographical overlap of the two pathogens in East
Africa found that those who live in areas of high P. falciparum
incidence have about twice the risk of being HIV infected
compared to individuals who live in areas of low incidence [9].
The host immune response to Plasmodium infection includes the
rapid release of interferon-gamma (IFN-c) by natural killer (NK)
cells and tumor necrosis factor (TNF) by macrophages, while cells
of the adaptive immune system release TNF, interleukin (IL)-12,
and IFN-c in response to parasitized erythrocytes [10]. Several
cytokines that are elaborated during acute bouts of malaria can
cause stimulation of HIV-1 replication. IL-1, IL-2, IL-3, IL-6, IL-
12, granulocyte macrophage-colony stimulating factor (GM-CSF),
and TNF-a/b have been identified as inducers of viral expression
[11], prompting speculation that cytokines involved in the control
and clearance of a Plasmodium infection, especially TNF-a, may
cause the increase in HIV replication [5].
We developed a culture system to evaluate interactions between
P. falciparum and HIV-1 in vitro using PBMCs collected from
humans experimentally infected with P. falciparum under carefully
controlled conditions in the context of a malaria human challenge
trial (personal communication). Using this model system, we were
able to further evaluate the mechanisms responsible for the
deleterious interactions between HIV-1 and P. falciparum, and to
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39000determine whether these interactions are affected by prior
exposure to P. falciparum.
Results
P. falciparum-infected Red Blood Cells (iRBCs) Stimulate
More HIV-1 p24 Ag Production than uRBCs
Whole PBMCs isolated from HIV uninfected, malaria naı ¨ve
donors produced significantly more HIV when co-cultured with
iRBCs than when co-cultured with uRBCs (Figure 1B inset,
p=0.0045, area under the curve comparisons). The increase in
HIV-1 production was evident by day 8 in culture. By day 10,
HIV production in the iRBC co-cultures was increased about 2.5-
fold over parallel co-cultures with uRBCs (Figure 1B).
Repeat Exposure to P. falciparum Enhances Stimulation
of HIV Production by iRBCs
To study the effects of acute P. falciparum infection on HIV-1
p24 Ag production by PBMCs after in vitro infection with HIV-1,
we used PBMCs isolated from the controlled human malaria
challenge participants. As noted above, all samples from any given
study participant were thawed and studied in the same experi-
ment. Sufficient PBMCs were available from 5 of the 6 malaria
challenge trial participants for the baseline, liver stage, and later
post-exposure time points and from 4 of the 5 participants at the
blood stage time point. Once thawed and cultured overnight, the
study design was identical to that described above. Figure 1C
depicts HIV production in the iRBC/uRBC co-cultures for the 5
participants at the 6 different visits. For all of the participants at
the baseline, liver stage, and blood stage visits, the amount of HIV
produced from the PBMCs co-cultured with iRBCs (pink lines)
was about 2 fold higher than the amount of HIV produced from
the PBMCs co-cultured with uRBCs (grey lines). For all
participants at the convalescent visits (day 35, 56, and 90 post
malaria exposure time points), HIV production from the iRBC co-
cultures (burgundy lines) was about 3 fold higher than that from
the respective PBMCs co-cultured with uRBCs (black lines).
In order to further explore the relationship between P. falciparum
stimulation and HIV-1 production by cells collected from malaria-
exposed volunteers, we performed an area-under-the-curve
Figure 1. Plasmodium falciparum enhances HIV-1 production. A. Schematic representation of controlled P. falciparum infection. B. HIV
production, as measured by p24 antigen concentration in the supernatants from PBMCs co-cultured with P. falciparum infected (iRBC, red line) or
uninfected red blood cells (uRBC, black line). Inset shows area under the curve (AUC) comparisons of the amount of HIV p24 Ag produced in the iRBC
versus uRBC co-cultures for 6 naı ¨ve donors averaged in the graph (Error bars represent SEM, p-value was determined with a paired two-tailed T-test).
C. HIV production from PBMCs that were isolated at the 6 different visits from study participants and placed into co-culture with either iRBCs or
uRBCs. Pink and black lines represent the means for the 5 participants (the blood stage time point included only 4 participants) at the three earliest
time points (D0, D5, day of first parasitemia) and the burgundy and grey lines represent the means of the convalescent time points (,D35, D56, D90),
error bars represent the SEM. D. AUC comparisons of HIV production from the iRBC (red) and uRBC (black) co-cultures at all 6 visits. HIV production in
the iRBC co-cultures is greater than the HIV production in the uRBC co-cultures at each visit; HIV produced in iRBC post-exposure co-cultures is
greater than that produced in the iRBC co-cultures at the 3 early visits (p,0.001 day 35, p=0.004 day 56, and p=0.017 day 90 post-exposure). Each
point is the mean for the 5 donors at that visit; the error bars represent the 95% confidence interval. p-values were determined using a repeated
measures ANOVA, corrected for multiple comparisons.
doi:10.1371/journal.pone.0039000.g001
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each condition and evaluated serial differences for each patient.
There was a significantly greater amount of HIV produced at each
time point in the iRBC co-cultures compared to the uRBC co-
cultures (p,0.001, Figure 1D). The amount of HIV produced
from the uRBC co-cultures (black line) was unchanged across all
the visits. In contrast, we observed a significant increase in HIV
production when iRBCs were co-cultured with PBMCs collected
at the day 35 (p,0.001), day 56 (p=0.004), and day 90 (p=0.017)
post-exposure visits, compared to iRBCs co-cultured with PBMCs
collected at earlier time points. Because the enhanced HIV
production occurred after chloroquine-mediated clearance of
parasitemia in the study participants, our results suggest that
development of malaria specific cellular immunity, rather than
activated effector cells, are responsible for the heightened HIV
production. In order to determine if CD4+ memory T-cells were
Figure 2. Plasmodium falciparum stimulates enhanced secretion of TNF-a, IFN-c, and MIP-1a, but not IL-6. PBMCs from the malaria
challenge trial participants were infected with HIV and co-cultured with iRBC and uRBC at the 6 visits as described earlier. Cytokine secretion in the
iRBC (red lines) and uRBC (black lines) co-culture supernatants was measured using the BioPlex platform. Cytokine production was measured at days
1, 4, 6, and 8 post initiation of co-culture and the area under the curve was calculated for each participant at each visit and plotted in A – D as the
average for the 5 participants, error bars represent the 95% CI. Repeated measures ANOVA was used to determine significance in the difference in
amount of cytokines secreted (iRBC-uRBC) at the post-exposure time points compared to the difference in amount of cytokine secreted (iRBC-uRBC)
at baseline. p-values have been corrected for multiple comparisons: TNF-a day 35 p=0.013, day 56 p=0.29, day 90 p=0.19; IFN-c day 35 p,0.001,
day 56 p=0.019, day 90 p,0.001; MIP-1a day 35 p,0.001, day 56 p=0.002, day 90 p,0.001. There was an increase in TNF-a, IFN-c, and MIP-1a (A–
C) secretion in the iRBC co-cultures compared to the uRBC co-cultures at all time points and an enhanced secretion at the convalescent time points.
There was no difference in IL-6 secretion (D).
doi:10.1371/journal.pone.0039000.g002
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compared surface activation markers on total CD4+ T-cells,
memory (CD45RO+) CD4+ T-cells, as well as total CD8+ T-cells
and memory (CD45RO+) CD8+ T-cells in PBMCs obtained on
Day 56 post-malaria exposure compared to surface activation
markers expressed by these cell types when obtained from malaria
naı ¨ve donors. Limitations in the number of available baseline
PBMC samples from the malaria exposed participants precluded a
matched longitudinal study to examine differences in memory cell
activation to malaria antigens. In these experiments, cells were
analyzed at 48, 72, and 96 hours post co-culture with either iRBCs
or uRBCs for surface expression of cellular activation markers
(Figure S1). We observed a general trend toward increased CD4
memory T-cell activation in the Day 56 malaria exposed donor
PBMCs compared to naı ¨ve control PBMCs after 72 and 96 hours
(Figure S1B). Statistical significance was noted with the CD25 (at
72 hours, p=0.046), CD69 (at 48 hours, p=0.008; at 72 hours,
p=0.034) and CD38 (at 72 hours, p=0.011; at 96 hours,
p=0.003) markers but not with the HLA-DR marker or among
HLA-DR/CD38 double positive cells. Within the total CD4 cell
population, we noted only upregulation of CD25 (p=0.018) and
CD69 (p=0.027) in the P. falciparum exposed donor PBMCs
compared to naı ¨ve control PBMCs at the 72 hour time point
(Figure S1A). There were not sufficient PBMCs from the malaria
challenge trial participants to assess T-cell activation in cells
cultured with media alone. In the cells from the malaria naı ¨ve
donors, we saw no difference in the amount of CD4 or CD8
activation for any of the markers in the media alone condition
compared to the uRBC condition (data not shown).
Increase in TNF-a, IFN-c, and MIP-1a Secretion is
Enhanced in iRBC Co-cultures Following in vivo Infection
with P. falciparum
We then measured cytokine production in culture supernatants
to examine relationships between HIV production and cytokine
secretion. We measured the secretion of 7 different cytokines: IL-4,
IL-6, IL-10, IL-17, TNF-a, IFN-c, and MIP-1a. The levels of IL-
4, IL-10, and IL-17 secretion were below the limit of detection of
the BioPlex assay (data not shown). Increases in the secretion of
TNF-a, IFN-c, and MIP-1a were observed in the co-cultures that
had been established with iRBCs compared to uRBCs. Production
of these cytokines was further increased in PBMCs obtained 35,
56, and 90 days post malaria challenge compared to those
obtained at baseline or at early stages of P. falciparum infection
(Figure 2A–C, TNF-a: day 35 p=0.013, day 56 p=0.29, day
90 p=0.19; IFN-c: day 35 p,0.001, day 56 p=0.019, day
90 p,0.001; MIP-1a: day 35 p,0.001, day 56 p=0.002, day
90 p,0.001). These cytokine profiles closely mirror the HIV
production profiles in Figure1D. IL-6 secretion was similar in
iRBC and uRBC co-cultures (Figure 2D).
Systemic Inflammation does not Correlate to Increased
HIV Production in the Co-cultures
In order to evaluate whether increases in HIV production at the
later time points might be related to generalized immune
activation following recovery from acute P. falciparum,w e
measured levels of C-Reactive Protein (CRP) in plasma obtained
at the time of PBMC isolation. For all but one participant (011-3),
levels of CRP appear to be higher during the early time points
than at the later time points (Figure 3). Thus, CRP levels were
generally higher during active infection compared to convalescent
samples, where HIV-1 was seen to increase. In fact, a spike in the
CRP levels was noted in two participants (018-4 and 016-6) at the
blood stage time point of the active malaria infection, but there
was no corresponding increase in HIV production at the same
time point. This supports the concept that increased HIV
production during the convalescent phase is not the result of
systemic inflammation.
Discussion
Using PBMCs and plasma collected from donors before, during
and after controlled infection with P. falciparum, we explored
interactions between HIV-1 and P. falciparum. We confirm that
iRBCs co-cultured with PBMCs from malaria naı ¨ve donors
enhance replication of HIV-1, and show that HIV-1 production is
further enhanced in PBMCs collected in the convalescent period
after experimental infection with P. falciparum. HIV-1 replication
after exposure to P. falciparum infected erythrocytes was accompa-
nied by increased secretion of pro-inflammatory cytokines TNF-a,
IFN-c, and MIP-1a, which was also enhanced after experimental
P. falciparum infection. In addition, we noted a trend toward
increased memory CD4+ T-cell activation in response to iRBCs
during the convalescent period. Enhanced HIV production in vitro
following controlled human infection with P. falciparum was not
associated with systemic inflammation in vivo as assessed by plasma
C-reactive protein levels.
Under the controlled conditions of the standard human
challenge model [12–14], subjects are diagnosed and treated at
low parasite density, often prior to the onset of clinical symptoms
and likely prior to the development of the cytokine storm observed
in severe bouts of clinical malaria in non-immune individuals [15].
Despite the limited duration of parasitemia in the experimental
malaria infection, production of HIV-1 by P. falciparum-exposed
PBMCs was substantially enhanced following treatment and
resolution of the blood stage of infection. Although not examined
in these initial experiments, the changes we observed might have
been more pronounced had study participants progressed to
clinical disease. Our data suggests that T-cell activation in these
participants was modest at the time parasitemia was first
demonstrated on peripheral blood smears, although flow cytom-
etry was not performed longitudinally to assess levels of activation
of unstimulated T-cells before and after experimental infection. It
has previously been shown that chloroquine reduces the number
of activated CD8+ memory T-cells and, to a lesser extent, CD4+
memory T-cells in the peripheral blood and inhibits the
production and secretion of TNF-a [16,17]. Since the participants
in the malaria challenge trial received chloroquine after the blood
stage blood draw, PBMCs isolated at the first three time points
were free of the immunomodulatory effects of chloroquine.
PBMCs collected at the later post-exposure time points (days 35,
56, and 90) might have been exposed to varying levels of
chloroquine (in view of its biological half-life of 1–2 months). Thus,
although chloroquine may have immunomodulatory effects, the
time points at which we noted enhancement of HIV-1 production
were those when it might have been present and we would have
expected immunomodulatory effects of chloroquine to exert an
effect opposite to that which we observed.
The role of cytokines during malaria has been extensively
studied. In controlled Plasmodium infections of malaria-naı ¨ve
subjects, serum levels of pro-inflammatory cytokines, including
TNF-a, IL-6, IFN-c, and IL-12p40, increase at the time that
parasites emerge from the liver and at the first appearance of
parasitized erythrocytes [10]. McCall et al. reported that PBMCs
isolated from participants who were infected with P. falciparum in a
controlled human malaria infection and exposed to cryopreserved
iRBCs secreted higher levels of IFN-c by NK cells than naı ¨ve
P. falciparum Enhances HIV Replication
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In semi-immune individuals living in malaria endemic areas, the
amount of IFN-c secreted is lower upon repeat exposure to
malaria antigens than in malaria naı ¨ve individuals, and malaria
episodes are less severe [19]. Separately, several TNF-a alleles
have been correlated to increased plasma TNF levels, increased
susceptibility to severe malaria [20], and increased susceptibility to
cerebral malaria [21]. Higher levels of circulating TNF-a were
found in adults and children with severe malaria compared to both
uncomplicated malaria cases and healthy individuals [20,22].
While IFN-c is a pro-inflammatory cytokine, it inhibits HIV
infection in vitro and has been used in patients with advanced AIDS
to reduce the number of opportunistic infections [23,24]. Thus,
even though both TNF-a and IFN-c are classified as pro-
inflammatory cytokines and even though both increase during
acute bouts of clinical malaria, TNF-a is a better candidate
cytokine than IFN-c to stimulate HIV production during P.
falciparum infection. Furthermore, peak plasma levels of TNF-a do
not decrease with repeat P. falciparum infections while those of IFN-
c decline with repeated infection.
Our data extend those of Xiao et al., who employed a similar
in vitro system to examine the effects of P. falciparum on HIV-1
production by CD8+ T-cell depleted PBMCs from malaria-naı ¨ve
individuals [25]. In their hands exposure to P. falciparum
merozoites and hemozoin increased HIV-1 replication [25]. In
our studies, in an effort to more closely mimic a natural malarial
infection, we stimulated unfractionated PBMCs with P. falciparum-
infected red blood cells rather than with merozoites or hemozoin.
In the model system reported by Xiao, HIV-1 replication was the
result of increased TNF-a production, but not the result of IL-6
production, demonstrated by the use of TNF-a and IL-6 blocking
antibodies. We also observed that TNF-a increased in iRBC co-
cultures compared to uRBC co-cultures and in post-exposure
iRBC cultures compared to the early cultures, while IL-6
production did not change significantly in any of these conditions.
Although there are clear-cut differences between the experimental
systems and although neither system fully captures all aspects of
natural infection, HIV-1 production was enhanced by P. falciparum
exposure under both sets of experimental conditions. It would be
of significant interest to further examine the cell types and
mechanisms driving the increase in HIV production in response to
P. falciparum stimulation.
Memory CD4+ T-cells have been an active area of inquiry in
the malaria field. Some have proposed that memory responses to
malaria are very short lived and that malaria specific CD4+ T-cells
are deleted, resulting in very little memory against future infection
[26,27]. Others have proposed that the apoptosis of antigen-
specific CD4 cells would be expected following resolution of acute
infection [28]. Animal models of malaria have shown that fully
functional memory CD4+ T-cells are maintained for prolonged
periods of time [29]. Recently, Wipasa et al. showed that malaria
specific CD4+ effector memory responses decay with a half-life of
about 3 years and that malaria specific CD4+ central memory
responses are maintained for at least six years after the last
documented clinical episode of malaria in humans [30]. If the
enhanced production of HIV-1 observed in our system is truly
attributable to the development of adaptive immune responses to
P. falciparum antigens, our results suggest that memory CD4+ T-
cells also develop in association with subclinical malarial infection
and that they persist for at least 90 days post-exposure.
Our study examined for the first time HIV-1 replication (in vitro)
induced by exposure to P. falciparum using samples derived from
human volunteers experimentally infected with malaria. As others
have demonstrated, malarial antigens increase HIV-1 replication
in vitro prior to experience with the parasite in vivo. We have
demonstrated that this increase is further enhanced following an
experimental infection with P. falciparum. These findings provide
experimental support to the clinical observations that plasma levels
of HIV-1 RNA rise during clinical bouts of malaria [3–5].
Although our study examined an initial exposure to P. falciparum,
persons living in regions endemic for P. falciparum undergo
repeated exposures to the parasite and serial bouts of clinical
illness. In the course of these repeated infections, P. falciparum-
specific CD4+ T-cells develop and play a critical role in
ameliorating morbidity and mortality [30–32]. In the setting of
HIV-1 infection it might be expected that pathogen specific CD4+
cells would be activated by malarial infection and, thus, would be
likely to be especially vulnerable to HIV-1 infection. Such an
Figure 3. General inflammation in the periphery does not correlate to HIV production in co-cultures. Generalized immunological
activation as assessed by C-Reactive Protein (CRP) levels in the plasma collected at the time of PBMC isolation in the five malaria challenge
participants. CRP was detected by ELISA. The light pink bars correspond to the early visits (baseline, liver stage, time of first parasitemia) and the
burgundy bars correspond to the three post-exposure time points (day 35, day 56, and day 90). The bars show the average CRP levels in the plasma at
the time of PBMCs isolation for the 5 participants. Error bars represent the SEM for the triplicate wells run at each time point. Levels of CRP in the
plasma did not increase at the post-exposure time points when the increase in HIV production was observed, suggesting that the increase in HIV
production was specific to malaria antigen re-exposure and not a result of generalized immune activation.
doi:10.1371/journal.pone.0039000.g003
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immunity and to contribute to enhanced replication of HIV-1 as
has been demonstrated both in the case of HIV-1 and M.
tuberculosis-specific immunity [33]. This unfortunate immunopath-
ogenic interaction would then form, at least in part, the basis for a
progressively more deleterious bidirectional clinical interaction
between these two pathogens with advancing HIV-1 associated
immunodeficiency.
Further studies are needed to more fully examine the
interactions between HIV-1 and P. falciparum infection both in
the clinic and in in vitro model systems. We believe that our studies
lend further support to the emerging evidence that these
pathogens are not indifferent to each other in areas where both
pathogens are endemic. This experimental culture system provides
a convenient platform in which to more carefully examine the
bidirectional interactions between these pathogens both in patients
with recurrent bouts of clinical malaria and in those with a
subclinical infection.
Materials and Methods
PBMC Collection and Isolation
PBMCs were isolated from human subjects enrolled in an
experimental malaria challenge trial (protocol MC-001) at the
Malaria Clinical Trials Center at Seattle Biomedical Research
Institute (personal communication). The experimental infection of
human subjects was conducted according to standard procedures
as previously described [34]. Briefly, healthy malaria-naı ¨ve adult
volunteers were infected with Plasmodium falciparum sporozoites
from bites of five P. falciparum (strain NF54)-infected A. stephensi
mosquitoes under controlled conditions. Volunteers were closely
monitored in the post-challenge period and treated with standard
doses of chloroquine phosphate (CQ) upon diagnosis of parasit-
emia by positive thick blood films. Blood sampling for isolation of
(PBMCs occurred prior to challenge (baseline) and at regular
intervals after challenge (Figure 1A) including day 5 (correspond-
ing to the liver stage of parasite development), the day of the first
positive blood smear (corresponding to the blood stage), and in the
post-treatment period approximately 35, 56, and 90 days following
mosquito bites. Cryopreserved PBMCs were thus available prior
to the challenge, during the liver and blood stage parasitemia, and
at three time points during convalescence.
PBMCs were isolated and cryopreserved according to standard
methods and frozen within 8 hours of venipuncture to ensure
optimal viability [35] under Good Clinical Laboratory Practices
(GCLP). Fresh PBMCs were isolated by Histopaque 1077
centrifugation and cultured overnight at 37uCi n5 %C O 2 in IL-
2/PHA free media (10% FBS, 1% Pen-Strep in RPMI 1640) and
used the following day in co-cultures. Frozen PBMCs were isolated
at each designated collection point and cryopreserved in 10%
DMSO/90% FBS and stored at 280 C until use in the designated
assay. Fresh PBMCs were obtained from malaria naı ¨ve donors
enrolled in a separate protocol (HS103) at Seattle Biomedical
Research Institute. Both protocols were approved by the Western
Institutional Review Board.
Co-cultures
On the day of study, PBMCs from all time points from a given
volunteer were thawed and placed in R10 media overnight (10%
FBS, 1% Pen-Strep, 1% L-Glutamine, RPMI 1640). The day
following the thaw, PBMCs were placed in 96-well plates
(2610
5 cells/well/200 mL) and infected with HIV-1 (San Diego
field isolate S-144; MOI=25) without exogenous mitogens or
cytokines in R20 media (20% FBS, 1% Pen-Strep). Red blood cells
(either P. falciparum infected or uninfected) were then added to
selected wells in a 10:1 ratio of RBCs to PBMCs (2610
6 RBCs/
well/200 mL). All conditions were run in triplicate. After 22 hours,
the entire 200 mL of media was collected and replaced with new
media to eliminate excess virus. 100 mL of the culture supernatants
was collected at days 4, 6, 8 and 10 and replaced with fresh
medium. These supernatants were frozen at 280uC and used to
determine HIV p24Ag and cytokine levels. Viral production was
quantified by determining amount of p24 antigen in the culture
supernatants by p24 Antigen capture ELISA (Perkin Elmer) by the
UCSD CFAR Translational Virology Core.
Plasmodium Falciparum Culture
P. falciparum NF54 parasites were grown in type O human RBCs
(obtained from malaria naı ¨ve donors enrolled in blood draw
program (protocol HS103) at Seattle Biomedical Research
Institute) in RPMI 1640 (Invitrogen) with 5 g/L albumax
(Invitrogen), 2 g/L dextrose (Fisher), 50 mg/L hypoxanthine
(Sigma), 2.25 g/L sodium bicarbonate (Sigma), 11 mg/L genta-
mycin (Invitrogen), and 5% pooled human AB serum (Valley
Biomedical). Parasite chambers were gassed with 5% O2/5%
CO2/90% N2 and incubated at 37uC. Parasite cultures were
maintained continuously and split 1–2 days prior to setting up co-
cultures, uRBCs were also placed into culture on the same day as
iRBCs were split. Unwashed iRBCs were used once 6–7% of the
RBCs in the culture were parasitized as assessed by light
microscopy. P. falciparum stage was not synchronized. Cultures
were routinely monitored for mycoplasma contamination by PCR
(Takara) and shown to be mycoplasma free.
Cytokine Quantification
Cytokine levels were measured in culture supernatants using a
BioPlex platform (BioRad). A 6-plex kit containing IL-10, IL-17,
IL-6, TNF-a, IFN-c and MIP-1a or a 5-plex kit containing IL-4,
IL-6, TNF-a, IFN-c and MIP-1a was used according to the
manufacturer’s protocol. Briefly, the antibody coupled beads were
mixed with 50 mL of the collected supernatants, which were
diluted 1:2 with media and incubated on a shaker for 30 minutes.
After three washes, the detection antibodies were added and the
plate was incubated on the shaker for 30 minutes. After another
three washes, Streptavidin-PE was added to each well and plates
were incubated on the shaker for 10 minutes. The beads were
resuspended in 1% formaldehyde in assay buffer and after a 30
second shake the plate was read on a Bioplex200 (BioRad). An 8-
point standard curve was used to determine cytokine concentra-
tions using a 5 parameter logistic regression curve. Detection limits
for cytokines are as follows: IL-4, 0.7 pg/mL; IL-6, 2.6 pg/mL;
IL-10, 0.3 pg/mL; IL-17, 3.3 pg/mL; IFN-c, 6.4 pg/mL; TNF-a,
6.0 pg/mL; MIP-1a, 1.6 pg/mL.
CRP ELISA
CRP Quantikine Kit (R&D) was used to quantify the CRP in
the plasma of the participants. Briefly, plasma (diluted 1:100) was
added to a 96 well plate pre-coated with anti-human CRP
antibodies and incubated at room temperature for 2 hours. The
plate was washed 4 times with wash buffer. A horseradish
peroxidase-conjugated CRP antibody was added and incubated at
room temperature for 2 hours. Followed by another 4 washes with
wash buffer, color solutions A and B were added in equal amounts
and were allowed to incubate at room temperature for 30 minutes
at which point a stop solution was added. The plate was read at
450 nm and a plate correction was read at 540 nm. The log10 of
the concentration for the standards was plotted against the log10 of
the respective OD values and a regression line was obtained that
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values for the unknowns.
Flow Cytometry
PBMCs were collected, frozen, and then thawed as described
above. PBMCs from day 56 post malaria challenge and from
malaria naı ¨ve donors were plated (2610‘5 PBMCs/well) in a 96
well plate and co-cultured with either iRBCs or uRBCs
(2610‘6 RBCs/well) in triplicate. Cultures were incubated at
37uC, 95% O2 for 48, 72, or 96 hours. At the indicated time point,
all three wells for a given condition were combined into a single
FACS tube. Cells were washed once in FACS buffer (PBS +2%
FBS), resuspended in 50 mL of Live/dead – Aqua stain
(Invitrogen) and stained with either CD3-FITC (eBioscience),
CD4-Pacific Blue (eBioscience), CD8-APC (BD Pharmingen),
CD45RO-PE (BD Pharmingen), HLA-DR-PerCP (Biolegend),
and CD38-PE-Cy5.5 (BD Pharmingen) or CD3-FITC, CD4-
Pacific Blue, CD8-APC, CD45RO-PE, CD69-PerCP-Cy7
(eBioscience), and CD25-PE-Cy5.5 (eBioscience). Cells were
stained at room temperature for 20 minutes and washed twice
with FACS buffer. The red blood cells were then lysed using
120 mL of BD FacsLyse at room temperature for 15 minutes,
washed once with PBS and resuspended in 130 mLo f2 %
formaldehyde in distilled H2O. Samples were subjected to flow
cytometric analysis within 18 hours of fixing on the BD LSRII. All
data were analyzed using FlowJo (Treestar).
Statistical Methods
Total HIV-1 p24Ag and cytokine production were calculated
over the 10 days in culture using a trapezoidal method (area under
the curve). Log-transformed HIV p24Ag and cytokine production
were compared between the iRBC and uRBC groups at each time
point following HIV infection of co-cultures to which iRBCs or
uRBCs had been added, and between earlier and later time points
following exposure, using a subject-specific random intercepts
ANOVA model including time (as a factor), group (iRBC versus
uRBC), their interaction, and a random subject effect. Therefore,
different mean values were allowed at each time point and for each
of the two groups for the log10 p24 AUC values, while correlation
of data points measured for the same subject was modeled by a
normally-distributed random intercept. The main comparisons of
interest between the iRBC and uRBC groups were of the change
in mean log10 p24 AUC between baseline and later stages. These
were evaluated by the Wald test, with a Bonferonni correction for
multiple comparisons. Graphs were made in GraphPad Prism
Software.
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Supporting Information
Figure S1 Activation of memory and total CD4/8 T-
cells by iRBCs in D56 post malaria challenge PBMCs.
PBMCS were cultured with iRBCs or uRBCs (without HIV) for
48, 72 or 96 hours. Cells were stained with either CD3-FITC,
CD4-Pacific Blue, CD8-APC, CD45RO-PE, HLA-DR-PerCP,
and CD38-PE-Cy5.5 or CD3-FITC, CD4-Pacific Blue, CD8-
APC, CD45RO-PE, CD69-PerCP-Cy7, and CD25-PE-Cy5.5 and
acquired using an LSRII. The percent of cells activated by iRBCs
was normalized to the amount of activation due to uRBCs; this
value was then logged and plotted. Line and error bars represent
the mean and standard error of the mean. All values above the
dotted line represent stimulation due to iRBCs. p-values were
determined using an unpaired, two-tailed T-test. A. CD4 cells
from the D56 post-malaria exposure PBMCs only show increased
expression of CD25 (p=0.018) and CD69 (p=0.027) at 72 hours
and there are no obvious trends toward increased activation in the
malaria exposed PBMCs. B. While expression of CD 69 at 48
hours (p=0.008), CD38 (p=0.011), CD25 (p=0.046), and CD69
(p=0.034) at 72 hours and CD38 (p=0.003) at 96 hours are
significantly increased in CD4+CD45RO+ D56 post malaria
challenge PBMCs compared to naı ¨ve controls at 72 hours, there is
also a trend toward increased activation in the HLA-DR/CD38
double positive cells in the PBMCs from malaria exposed donors
compared to naı ¨ve controls at both 72 and 96 hours post co-
culture in the memory CD4 compartment. C – D. For the total
and memory CD8 T-cells, there is increased activation in the
malaria exposed Day 56 PBMCs at 72 and 96 hours compared to
naı ¨ve controls. For total CD8 cells at 72 hours, there is increased
expression of CD38 (p=0.016) and CD69 (p=0.001); at 96 hours,
there is increased expression of HLA-DR/CD38 double positives
(p=0.025) and CD38 alone (p=0.015). For memory CD8 cells at
72 hours, there is increased expression of CD38 (0.036) and CD69
(0.001); at 96 hours, there is increased expression of CD38 alone
(p=0.0003).
(TIF)
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